Pharmaceutical Cannabis - Chile

Chile

Revenue in the Pharmaceutical Cannabis is projected to reach US$9.94m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 5.47%, resulting in a market volume of US$12.97m by 2029.
In global comparison, most revenue will be generated in the United States (US$913.10m in 2024).
In relation to total population figures, per person revenues of US$19.30k are generated in 2024.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceutical Cannabis market in Chile has been experiencing significant growth and development in recent years.

Customer preferences: Customers in Chile have shown a growing interest in pharmaceutical cannabis products due to increasing awareness about the potential health benefits associated with cannabis-based treatments. The shift towards natural and alternative medicine has also influenced consumer preferences, with many seeking out cannabis products for various medical conditions.

Trends in the market: One noticeable trend in the Pharmaceutical Cannabis market in Chile is the increasing acceptance and legalization of medical cannabis. This has opened up opportunities for pharmaceutical companies to introduce a wide range of cannabis-based products to cater to the growing demand in the country. Additionally, the government's efforts to regulate the market and ensure product quality and safety have further contributed to the market's expansion.

Local special circumstances: Chile's unique geographical location and climate conditions provide an ideal environment for cannabis cultivation, allowing local producers to cultivate high-quality cannabis for pharmaceutical purposes. The country's progressive regulations and supportive government policies have also played a crucial role in driving the growth of the Pharmaceutical Cannabis market in Chile.

Underlying macroeconomic factors: The growing Pharmaceutical Cannabis market in Chile can also be attributed to favorable macroeconomic factors such as increasing disposable income levels, a growing elderly population with chronic health conditions, and a shifting healthcare landscape towards more personalized and natural treatment options. These factors have created a conducive environment for the expansion of the pharmaceutical cannabis industry in the country.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.